The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Because atherosclerosis is a systemic disease process, it is not surprising that cardiologists find themselves treating patients with peripheral vascular problems in addition to the more traditional cardiovascular issues. Of the 64.4 million Americans with cardiovascular disease, 8–12 million are affected by peripheral arterial disease (PAD), which is estimated to encompass 12–20% of Americans over...
Clinical trials with HMG-CoA reductase inhibitors have reported decrease in clinical events out of proportion to small anatomical changes in coronary angiogram. Previous finding from our lab has shown that HMG-CoA reductase inhibitors cause a rise in IgG autoantibodies to oxidized LDL(ox-LDI) during the first 6 months of therapy. However, the autoantibodies titers decrease by 12 months. We examined...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.